Hui Miao
Directeur/Membre du Conseil chez Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
Postes actifs de Hui Miao
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
 Beijing Zhendong Langdi Pharmaceutical Co., Ltd. Pharmaceuticals: OtherHealth Technology Part of Fountainvest Partners (Asia) Ltd., Beijing Zhendong Langdi Pharmaceutical Co., Ltd. manufactures medicinal chemicals and botanical products. The company is based in Beijing, China. Beijing Zhendong Langdi Pharmaceutical Co. was acquired by Shanghai Fanglang Enterprise Management Co. Ltd. from Shanxi Zhendong Pharmaceutical Co., Ltd. on October 28, 2021 for $895.09 million. The Chinese company was founded in 2003. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Hui Miao
Anciens postes connus de Hui Miao
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. | Directeur/Membre du Conseil | 17/10/2022 | 09/04/2024 |
| Directeur Général | 01/07/2022 | 09/04/2024 | |
| Corporate Officer/Principal | 01/07/2022 | 23/09/2022 | |
| President | 23/09/2022 | 09/04/2024 |
Formation de Hui Miao
| Renmin University of China | Undergraduate Degree |
Statistiques
Internationale
| Chine | 4 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
Beijing Zhendong Langdi Pharmaceutical Co., Ltd. Pharmaceuticals: OtherHealth Technology Part of Fountainvest Partners (Asia) Ltd., Beijing Zhendong Langdi Pharmaceutical Co., Ltd. manufactures medicinal chemicals and botanical products. The company is based in Beijing, China. Beijing Zhendong Langdi Pharmaceutical Co. was acquired by Shanghai Fanglang Enterprise Management Co. Ltd. from Shanxi Zhendong Pharmaceutical Co., Ltd. on October 28, 2021 for $895.09 million. The Chinese company was founded in 2003. | Health Technology |
